Sanofi moves on Lemtrada; Novartis Indian patent case
05:32 EDT 21 Aug 2012 | thePharmaLetter
French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia drug Campath (alemtuzumab) from the market to prepare for its launch under a different dosage and as a multiple sclerosis treatment that will be..
Original Article: Sanofi moves on Lemtrada; Novartis Indian patent case
More From BioPortfolio on "Sanofi moves on Lemtrada; Novartis Indian patent case"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
